Search

Your search keyword '"Darras, Basil T"' showing total 907 results

Search Constraints

Start Over You searched for: Author "Darras, Basil T" Remove constraint Author: "Darras, Basil T"
907 results on '"Darras, Basil T"'

Search Results

1. Hepatocyte-intrinsic SMN deficiency drives metabolic dysfunction and liver steatosis in spinal muscular atrophy

2. Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA

4. Dystrophinopathies

5. Variants in DTNA cause a mild, dominantly inherited muscular dystrophy

7. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study.

9. Seven-Year Experience From the National Institute of Neurological Disorders and Stroke–Supported Network for Excellence in Neuroscience Clinical Trials

11. Beyond Contractures in Spinal Muscular Atrophy: Identifying Lower-Limb Joint Hypermobility

12. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

15. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes

16. Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study.

17. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls.

18. Health related quality of life in young, steroid-naïve boys with Duchenne muscular dystrophy

19. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen

20. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial

21. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study

25. Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3

26. Nusinersen Treatment in Adults with Spinal Muscular Atrophy

28. Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability.

29. Identifying Biomarkers of Spinal Muscular Atrophy for Further Development

30. Erratum to: Patients with Spinal Muscular Atrophy Type 1 Achieve and Maintain Bulbar Function Following Onasemnogene Abeparvovec Treatment

31. Nusinersen Treatment of Children with Later-Onset Spinal Muscular Atrophy and Scoliosis Is Associated with Improvements or Stabilization of Motor Function

33. List of contributors

35. Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!

37. Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study

40. Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)

43. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

48. X-linked myotubular myopathy: A prospective international natural history study

50. Developmental milestones in type I spinal muscular atrophy

Catalog

Books, media, physical & digital resources